OliX Pharmaceuticals Inc

OliX Pharmaceuticals Inc has a market capitalization of 3,042,615,368,100 KRW and a price-to-book ratio of 20.37, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 6.6, suggesting strong short-term liquidity, but its operating cash flow of -15,899,886,730 KRW and free cash flow of -15,146,162,600 KRW indicate ongoing cash outflows. The debt-to-equity ratio of 0.16 reflects a relatively low leverage position, with long-term debt of 23,286,619,680 KRW compared to total equity of 149,379,304,630 KRW. The company's profitability metrics are negative, with a return on equity of -0.1054 and a return on assets of -0.0806, indicating that it is not generating returns for shareholders or asset holders. The operating income of -30,055,021,130 KRW and net income of -15,742,651,460 KRW further underscore the company's unprofitable operations. The EV/EBITDA ratio of -102.01 and EV/Revenue ratio of 209.04 suggest that the company is not currently generating positive earnings and is valued at a high multiple of its revenue. OliX Pharmaceuticals Inc's revenue of 14,666,854,280 KRW is derived from undisclosed segments and geographic regions, as the input data does not provide specific details on revenue concentration or geographic exposure. The absence of segment-specific data limits the ability to assess the company's diversification and potential risks associated with over-reliance on a single product or market. The company's growth trajectory is uncertain, with no specific numeric deltas provided in the outlook for the current or next fiscal year. Analyst estimates suggest a mean revenue estimate of 8,000,000,000 KRW, which is significantly lower than the last actual revenue of 14,667,000,000 KRW, indicating potential challenges in maintaining revenue growth. The mean EBIT estimate of -31,000,000,000 KRW also suggests continued operational losses. The risk assessment for OliX Pharmaceuticals Inc highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to fund operations and meet short-term obligations. The dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings for OliX Pharmaceuticals Inc are not detailed in the input data, limiting the ability to assess the impact of recent developments on the company's financial position and strategic direction. The absence of specific information on recent events or transcripts prevents a comprehensive evaluation of the company's current status and future prospects.